We also tested the B-CLL cells of patient #3, an augmentable responder with both high CD59 and high CD20, whose B-CLL cells were lysed in the presence of both rituximab and the CFH mAb. Here, CD59 is linked to B-cell chronic lymphocytic leukemia.